Announced
Completed
Synopsis
Grunenthal, a pharmaceutical company, completed the acquisition of Crestor, a statin, a lipid-lowering medicine, from AstraZeneca, a biopharmaceutical company, for $350m. “This agreement supports the management of our mature medicines to enable reinvestment into the pipeline and bringing new, innovative treatments to patients. Grünenthal previously acquired the rights to several established AstraZeneca medicines and is well placed to ensure continued access to Crestor for patients across Europe," Ruud Dobber, Grunenthal BioPharmaceuticals Business Unit Executive Vice President.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.